標靶治療市場規模、佔有率和成長分析（按類型、應用、分銷管道和地區分類）－2026-2033年產業預測

全球標靶治療市場規模預計在 2024 年達到 752.5 億美元，從 2025 年的 773.6 億美元成長到 2033 年的 964.8 億美元，在預測期（2026-2033 年）內複合年成長率為 2.8%。

生物製藥日益普及和生物技術領域大量投資的推動，全球標靶治療藥物市場正快速擴張。單株抗體能夠有效抑制癌細胞增殖，已成為這波成長浪潮的關鍵因素。預計未來線上藥局的成長將有助於提高這些特定治療藥物的可及性和銷售量。此外，政府加大對先進醫療基礎設施的投入也將對市場成長發揮至關重要的作用。同時，大眾對標靶治療藥物認知度的不斷提高也持續刺激著市場需求。然而，標靶治療潛在的副作用等挑戰可能會阻礙市場的整體發展。總體而言，在不斷變化的醫療環境下，該市場有望實現強勁成長。

全球標靶治療市場促進因素

全球癌症發生率的上升推動了對創新治療方法的需求，從而顯著促進了全球標靶治療市場的成長。隨著越來越多的人被診斷出患有各種類型的癌症，對有效標靶治療的需求變得日益迫切。此外，消費者可支配收入的增加擴大了獲得先進醫療保健解決方案的機會，導致對標靶治療的投資激增。癌症病例的增加，加上患者經濟能力的提高，為標靶治療的研發和應用創造了有利環境，從而推動了市場的發展。

限制全球標靶治療市場發展的因素

全球標靶治療市場面臨許多挑戰，主要源自於標靶治療及其相關藥物的副作用。這些副作用的嚴重程度不一，從輕微到嚴重不等，且往往會影響患者的治療順從性和整體治療效果。由於這些治療方法的複雜性，可能導致難以預測的反應，因此醫療機構必須密切監測患者。此外，個別治療反應的差異也限制了市場發展，使得開發普適有效的治療方案變得困難。因此，解決這些問題對於標靶治療在臨床實踐中的持續發展和推廣至關重要。

全球標靶治療藥物市場趨勢

全球標靶治療市場正經歷強勁成長，主要得益於策略性產業聯盟、收購以及創新產品的推出。主要企業正致力於拓展產品組合，推出能提升多種疾病治療效果的先進治療方法。這種競爭格局不僅推動了創新，也刺激了市場動態，因為各企業都在努力滿足日益成長的醫療保健需求。對精準醫療的日益重視以及補體標標靶治療的開發，凸顯了該領域的變革性。隨著針對個別患者的個人化治療方案的不斷完善，標靶治療的價值提案也得到了進一步提升。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球標靶治療市場規模（按類型和複合年成長率分類）（2026-2033 年）

• 單株抗體
  • 血管新生抑制劑
  • HER-2標靶藥物
  • 抗CD20單株抗體
• 低分子化合物
  • 蛋白酪氨酸激酶抑制劑
  • mTOR抑制劑
  • PARP抑制劑

全球標靶治療市場規模（按應用及複合年成長率分類）（2026-2033 年）

• 乳癌
• 大腸直腸癌
• 白血病
• 肺癌
• 淋巴瘤
• 多發性硬化症
• 腎癌
• 老齡化黃斑部病變（濕性）
• 其他癌症（卵巢癌、輸卵管癌、攝護腺癌、胰臟癌）

全球標靶治療市場規模（按分銷管道分類）及複合年成長率（2026-2033 年）

• 醫院藥房
• 零售藥房
• 網路藥房

全球標靶治療藥物市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Roche（Switzerland）
• Novartis（Switzerland）
• Pfizer（USA）
• Merck & Co.（USA）
• Bristol-Myers Squibb（USA）
• AstraZeneca（UK）
• Amgen（USA）
• GlaxoSmithKline（UK）
• Sanofi（France）
• Bayer（Germany）
• Eli Lilly and Company（USA）
• Johnson & Johnson（USA）
• AbbVie（USA）
• Takeda Pharmaceutical（Japan）
• Gilead Sciences（USA）
• Biogen（USA）
• Regeneron Pharmaceuticals（USA）
• Celgene（USA）（Acquired by Bristol-Myers Squibb）
• Incyte（USA）

結論與建議

Global Targeted Therapeutics Market size was valued at USD 75.25 Billion in 2024 and is poised to grow from USD 77.36 Billion in 2025 to USD 96.48 Billion by 2033, growing at a CAGR of 2.8% during the forecast period (2026-2033).

The global market for targeted therapeutics is witnessing rapid expansion, driven by the rising popularity of biologics and significant investments in the biotechnology sector. Monoclonal antibodies have emerged as key players from this surge, effectively inhibiting tumor cell proliferation. The anticipated growth of online pharmacies is expected to enhance the availability and sales of these specific therapeutic drugs. Furthermore, increased government spending on advanced healthcare infrastructure will play a pivotal role in propelling market growth. Additionally, heightened public awareness regarding targeted therapeutics continues to stimulate demand. Nevertheless, the market faces challenges, including potential side effects associated with targeted therapies, which may hinder its overall progress. Overall, the landscape is poised for robust growth amid evolving healthcare dynamics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Targeted Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Targeted Therapeutics Market Segments Analysis

Global Targeted Therapeutics Market is segmented by Type, Application, Distribution Channel and region. Based on Type, the market is segmented into Monoclonal Antibodies and Small Molecule. Based on Application, the market is segmented into Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Sclerosis, Renal Cancer, Wet Age-related Macular Degeneration and Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, and Pancreatic Cancer). Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Targeted Therapeutics Market

The growth of the Global Targeted Therapeutics market is significantly propelled by the rising incidence of cancer worldwide, which has heightened the demand for innovative treatment options. As more individuals are diagnosed with various types of cancer, the need for effective targeted therapies becomes increasingly urgent. Additionally, the increasing disposable income of consumers allows for greater access to advanced healthcare solutions, leading to a surge in investment in targeted therapies. This combination of escalating cancer cases and improved financial capabilities among patients fosters a favorable environment for the development and adoption of targeted therapeutics, driving the market forward.

Restraints in the Global Targeted Therapeutics Market

The Global Targeted Therapeutics market faces significant challenges due to the side effects associated with targeted therapies and related drugs. These adverse effects can range from mild to severe, often impacting patient adherence and overall treatment outcomes. The complexity of these therapies can lead to unpredictable reactions, making it essential for healthcare providers to closely monitor patients. Additionally, the variability in individual responses to such treatments poses a restraint on market growth, as it complicates the development of universally effective therapeutic solutions. Thus, addressing these concerns is crucial for the continued advancement and acceptance of targeted therapeutics in clinical practice.

Market Trends of the Global Targeted Therapeutics Market

The global Targeted Therapeutics market is experiencing robust growth, driven by strategic collaborations, acquisitions, and innovative product launches within the industry. Leading companies are increasingly focusing on expanding their portfolios through the introduction of advanced therapies, which enhance treatment efficacy for various diseases. This competitive landscape not only fosters innovation but also stimulates market dynamics, as firms strive to meet rising healthcare demands. The growing emphasis on precision medicine and the development of complement-targeted therapies highlight the transformative nature of this sector, where specialized treatments are increasingly tailored to individual patient needs, thereby reinforcing the value proposition of targeted therapeutics.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Targeted Therapeutics Market Size by Type & CAGR (2026-2033)

• Market Overview
• Monoclonal Antibodies
  • Angiogenesis Inhibitors
  • HER-2 Targeted Agents
  • Anti-CD20 Monoclonal Antibodies
• Small Molecule
  • Tyrosine Kinase Inhibitors
  • mTOR Inhibitors
  • PARP Inhibitors

Global Targeted Therapeutics Market Size by Application & CAGR (2026-2033)

• Market Overview
• Breast Cancer
• Colorectal Cancer
• Leukemia
• Lung Cancer
• Lymphoma
• Multiple Sclerosis
• Renal Cancer
• Wet Age-related Macular Degeneration
• Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, and Pancreatic Cancer)

Global Targeted Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Targeted Therapeutics Market Size & CAGR (2026-2033)

• North America (Type, Application, Distribution Channel)
  • US
  • Canada
• Europe (Type, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene (USA) (Acquired by Bristol-Myers Squibb)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations